Evolving spectrum and incidence of non-AIDS-defining malignancies.

Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA.
Current opinion in HIV and AIDS (Impact Factor: 4.39). 02/2009; 4(1):27-34. DOI: 10.1097/COH.0b013e32831a7259
Source: PubMed

ABSTRACT Non-AIDS defining cancer (NADC) has emerged as an important cause of morbidity and mortality in the HIV-infected population. Insight into the incidence, spectrum, risk factors, management, and outcome of these cancers has continued to emerge. The recent literature on this topic is reviewed.
Several recent studies have explored the shifting spectrum of NADC in both developed and underdeveloped regions of the world. Investigators have shown only a minor difference in the geographic spectrum of NADC. Although several NADC have continued to occur at rates significantly higher than expected, a noticeable decline was observed in other cancers despite antiretroviral therapy. Factors other than HIV and immunosuppression proved to be important in the risk, treatment response, and outcome of these neoplasms. Studies dealing with the management of several NADC were published, including the role of highly active antiretroviral therapy (HAART).
An increased overall relative risk of developing NADC continues to be reported in the HIV-infected population worldwide. The development of NADC appears to be multifactorial. Although control of HIV viremia has proven to be beneficial, the impact of HAART on NADC incidence rates and survival is not uniform. Further effort is needed to resolve the direct and indirect effects of HIV on NADC in order to guide effective prevention and treatment strategies of these malignancies.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background This study provides an estimate of the proportion of HIV-positive patients in Italian clinics showing an ‘adverse prognosis’ (defined as a CD4 count ≤200 cells/L or an HIV RNA >50 HIV-1 RNA copies/mL) over time, and investigates whether this proportion varied according to patients' characteristics. Methods We estimated the annual proportion of patients with a CD4 count ≤200 cells/L or HIV RNA >50 copies/mL out of the total number of patients in the Icona Foundation cohort seen in any given year, both overall and after stratifying by demographical and treatment status groups. Generalized estimating equation models for Poisson regression were applied. Results In 1998–2008, the prevalence of patients with a CD4 count ≤200 cells/L decreased from 14 to 6% [adjusted relative risk (RR) 0.86/year; 95% confidence interval (CI) 0.84–0.88; P50 copies/mL decreased from 66 to 40% (adjusted RR 0.95/year; 95% CI 0.95–0.96; PPThere was a substantial increase in the success rate of ART in Italy in 1998–2008, resulting in a lower percentage of patients with adverse prognosis in recent years. The use of ART seemed to be the most important determinant of viral load outcome, regardless of mode of transmission. Although injecting drug users showed a less marked improvement in CD4 cell count over time than other risk groups, they showed a similar improvement in detectable viral load.
    HIV Medicine 03/2011; 12(3). DOI:10.1111/j.1468-1293.2010.00866.x · 3.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer has become a growing burden on morbidity and mortality in human immunodeficiency virus (HIV)-infected individuals in the era of highly active antiretroviral therapy (HAART). The objectives of this study were to determine the rates and cancer predictors of a population of HIV-infected individuals and to draw some recommendations for cancer screening in these patients. This retrospective case-control study describes malignant cancers diagnosed in HIV-infected subjects at Hospital de Santa Maria and assesses cancer predictors in HIV-infected subjects using HIV-infected controls without cancer. A total of 225 patients were included in this study: 25 cancer cases and 200 controls. Eight HIV-infected controls without cancer diagnosis were selected for each cancer case. Besides cancer´s date of diagnosis and its histological type, we also recorded demographic data, medical history and HIV-related information. Cancers were grouped as AIDS-defining cancers (ADCs), and non-ADCs. Non-ADCs were further categorized as being infection related (NADC-IR) and unrelated (NADC-IUR). The majority of cancer cases were diagnosed in male patients (84%). The mean age of patients was higher in NADCs, mostly in NADCs-IUR, where almost half (43%) were infected with type 2 HIV. About half (52%) of cancer cases were ADCs (32% Kaposi sarcoma, 16% non-Hodgkin's lymphoma, and 4% cervical cancer). The most common NADCs were: lung, skin and hepatocellular carcinoma (8% each). In univariate analyses, immunosuppression, HBV coinfection, smoking and alcoholism were associated with ADCs. In multivariate analysis, alcoholism and higher HIV viral load remained independent predictors of ADCs. Longer duration of HIV infection, type 2 HIV and a longer history of HAART were associated with NADCs, in univariate analyses. Besides the evident multifactorial etiology, in this study ADCs appeared to be associated with immunosuppression, while NADCs seemed to be correlated by other oncogenic mechanisms such as chronic inflammation. Based on this study, cancer screening should be performed in these patients in Portugal.
    06/2012; 2(2):60-74. DOI:10.11599/germs.2012.1014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Review: Anal human papillomavirus and anal squamous cell cancer Southern Africa has the largest burden of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) in the world. Highly active antiretroviral therapy (HAART) is increasingly being made available in the region. The disease has shifted from being a death sentence to that of a chronic disorder with the availability of HAART. The morbidity and mortality in people living with HIV/AIDS (PLWHA) in the developed world seems to be shifting from that of opportunistic infection to malignancy, particularly non-AIDS-defining cancer. A similar trend may be imminent in the developing world owing to the availability of HAART. Squamous cell cancer of the anus is a cancer with a seemingly increasing incidence in PLWHA. This review explores the possible impact that a rise in the incidence of squamous cell cancer of the anus would have on the region, and strategies that may be employed to identify and counteract this escalation.

Full-text (2 Sources)

Available from
May 21, 2014